Fig. 2

The 3T3-L1 cell uptake and fat accumulation after treatment of CLA-loaded tocol NLCs with different sizes: (A) flow cytometry analysis of CLA-loaded tocol NLCs incubated with 3T3-L1 cells; (B) the quantification of intracellular uptake of CLA-loaded tocol NLCs calibrated by the fluorescence intensity of the nanoformulation itself; (C) Confocal microscopic images of CLA-loaded tocol NLCs (red), DAPI (blue), and LysoTracker (green) showing uptake of nanoparticles by 3T3-L1 cells (Scale bar = 50 μm); (D) intracellular CLA uptake by 3T3-L1 cells after treatment with CLA-loaded tocol NLCs and free form; (E) the cell viability after treatment of CLA-loaded tocol NLCs as determined by MTT assay; (F) the ORO staining of 3T3-L1 cells after treatment of CLA-loaded tocol NLCs with MDI stimulation (Scale bar = 100 μm); (G) the ORO quantification of 3T3-LI cells after treatment of CLA-loaded tocol NLCs with MDI stimulation; and (H) the intracellular TG content of 3T3-LI cells after treatment of CLA-loaded tocol NLCs with MDI stimulation. All data are presented as the mean of three experiments ± S.E.M. *** p < 0.001; ** p < 0.01 as compared to the control group or MDI-treatment group. ^##p < 0.01, ^#p < 0.05 between the free and nanoparticulate forms